Quantification and phenotyping of circulating tumor cells isolated with the GILUPI CellCollector® technology
GILUPI announces the release of a video article presenting an innovative approach for isolation of circulating tumor cel…
GILUPI announces the release of a video article presenting an innovative approach for isolation of circulating tumor cel…
GILUPI GmbH is pleased to announce its participation at the 2018 ISMRC (International Symposium on Minimal Residual Canc…
GILUPI GmbH announced that the company was granted a European patent protecting the unique and innovative GILUPI technol…
GILUPI announces the publication of a peer reviewed study about a new and promising mRNA-based assay that allows detecti…
GILUPI GmbH announces that Dr. Christian Jurinke is appointed to the position of CEO and together with Alexander Herrman…
GILUPI GmbH announces the recent publication of a clinical study demonstrating multiplex gene expression profiling of ci…
GILUPI GmbH announces the release of a scientific article about the detection of circulating tumor cells (CTCs) from blo…
GILUPI GmbH is pleased to announce its participation at the 2017 ACTC (Advances in Circulating Tumor Cells) congress. T…
GILUPI GmbH announces the recent publication of a clinical study demonstrates the isolation of circulating tumor cells (…
GILUPI GmbH announces that a scientific article about a multicenter, clinical trial in China has been published in the c…